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Abstract
Background: The National Comprehensive Cancer Network and the American Society of Clinical Oncology have
established guidelines for the treatment and surveillance of colorectal cancer (CRC), respectively. Considering these
guidelines, an accurate and efficient method is needed to measure receipt of care.
Methods: The accuracy and completeness of Veterans Health Administration (VA) administrative data were assessed
by comparing them with data manually abstracted during the Colorectal Cancer Care Collaborative (C4) quality
improvement initiative for 618 patients with stage I-III CRC.
Results: The VA administrative data contained gender, marital, and birth information for all patients but race
information was missing for 62.1 % of patients. The percent agreement for demographic variables ranged from
98.1–100 %. The kappa statistic for receipt of treatments ranged from 0.21 to 0.60 and there was a 96.9 %
agreement for the date of surgical resection. The percentage of post-diagnosis surveillance events in C4 also in
VA administrative data were 76.0 % for colonoscopy, 84.6 % for physician visit, and 26.3 % for carcinoembryonic
antigen (CEA) test.
Conclusions: VA administrative data are accurate and complete for non-race demographic variables, receipt of
CRC treatment, colonoscopy, and physician visits; but alternative data sources may be necessary to capture
patient race and receipt of CEA tests.
Keywords: Colorectal cancer, Cancer surveillance, Cancer treatment, Administrative data, Electronic medical
record, Veterans Health Administration
Background
Approximately 3,400 colorectal cancers (CRC) are diag-
nosed in the Veterans Health Administration (VA) each
year [1]. Considering CRC’s 5 year survival rate of
65.2 % [2], most of these veterans will become long-
term survivors. As such, the receipt of CRC-related
care, which includes curative intent treatment for CRC
(i.e. surgical resection, chemotherapy, and radiation) [3, 4]
as well as tests for assessment and surveillance after the
diagnosis of CRC (i.e. colonoscopy, physician visit, and
carcinoembryonic antigen (CEA) test) [5], is of broad inter-
est for both veteran and non-veteran populations [6–9].
An accurate and efficient method is needed to meas-
ure receipt of CRC-related care. Potential data sources
include surveys [10], health record review [11], and
health claims (billing) data [10, 12–17]. The VA uses an
electronic health record system, known as the Comput-
erized Patient Record System (CPRS), which allows
searching for procedure notes and other services within
a given patient record to determine what care has been
provided [18]. However, review of health records for re-
search purposes typically occurs on a facility by facility
basis because patient health records are not routinely
shared between medical centers except for direct patient
care. Use of health claims data has practical advantages
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in terms of access to large samples across multiple sites
and low incremental costs. Thus, in this methodologic
study, our objective was to compare the receipt of
CRC-related care in VA according to administrative
data compared with data from a manual chart abstrac-
tion of the electronic health record performed during a
quality improvement collaborative (EHR/QI) called the
Colorectal Cancer Care Collaborative (C4). C4 was
undertaken to improve processes of care delivery for
CRC [7, 19].
Administrative data has been compared with health
record review for receipt of cancer surveillance tests [12]
and colonoscopy [10] by Medicare patients; receipt of
colonoscopy prior to CRC diagnosis [17] and CRC sur-
gery [16] in Alberta, Canada; and receipt of colonoscopy,
surgery, chemotherapy, and radiation by CRC patients in
New South Wales, Australia [15]. But this study is the
first to attempt to validate the use of VA administrative
data for measuring the receipt of CRC treatment and
surveillance care. The objectives of this study are to
identify types of care in which the use of VA administra-
tive data to measure receipt of CRC-related care is rea-
sonably complete and accurate as well as measures in
which the VA administrative data may not be sufficiently
complete or accurate so alternative methods may be ne-
cessary to collect this data in studies involving VA data.
Methods
The study was approved by the Institutional Review
Board at Indiana University (0805–61), the VA research
committee at the Roudebush VA Medical Center, and
the Institutional Review Board at Louisiana Tech Univer-
sity (HUC 1048). The research is in compliance with the
Helsinki Declaration.
Data sources
C4 was a national quality improvement project involving
teams from 28 VA medical centers (VAMCs) with at least
one team from each of the 21 regional Veterans Integrated
Service Networks (VISNs) covering the entire U.S. (see
Jackson et al., 2013 [9] for a detailed description of the C4
manual data abstraction.). Briefly, C4 sites used local can-
cer registries or clinical patient lists to identify a cohort of
newly diagnosed CRC patients. C4 sites used an abstrac-
tion tool, called the Cancer Care Quality Measurement
System (CCQMS), to systematically guide retrospective
manual abstraction of approximately 230 data elements
from the VA’s Computerized Patient Record System
(CPRS). These elements were used to evaluate compliance
with 25 quality indicators, based upon National Compre-
hensive Cancer Network (NCCN) guidelines, for colon
and rectal cancer treatment. These quality indicators in-
clude receipt of curative intent CRC treatment and dates
of CRC-related tests received by individual patients (which
the current study uses to quantify the accuracy and com-
pleteness of VA administrative data for measuring the
receipt of this care). Abstractors were cancer registrars,
clinical, or administrative staff. The level of training and
number of abstractors varied between sites but data
variability was limited by a standard computerized data
abstraction tool, data definition documents, availability of
a centralized help desk, and training of abstractors [9]. A
validation of inter-observer health record abstraction ac-
curacy was not performed for the C4 study, but its data
abstractors reported a high level of confidence in knowing
what data needed to be entered, where to find the data in
medical records, and that the instructions were clear [9].
Study population
The study cohort included patients identified during C4
with an incident diagnosis of non-metastatic (AJCC
collaborative stage I, II, or III) CRC between January 1,
2004 and October 1, 2006 with complete data collection
in which all NCCN quality measures and surveillance
tests were evaluated by C4 abstractors. Follow-up care
data were collected by October 1, 2007. But, because
there was also no documentation of when each manual
search of the EHR/QI was conducted, we assumed that
the final search for a patient was conducted on the last
documented date in the EHR/QI data for that patient.
Patients with stage IV CRC were excluded from the
current study because these patients may not be eligible
for curative intent treatment and the American Society
of Clinical Oncology (ASCO) guidelines for CRC sur-
veillance care are more uniformly defined for patients
diagnosed with stage I-III CRC [5].
Electronic health record / quality improvement (EHR/QI) data
While all C4 study patients were eligible for data collec-
tion for at least 12 months after CRC diagnosis, the EHR/
QI data collection was non-systematic. Data abstractions
were not done at a fixed period of time after diagnosis.
Therefore, a patient’s data were censored at the latest date
recorded by the EHR/QI abstractor so only the period of
care reviewed by the abstractors was used for analysis.
Administrative data
VA administrative data were drawn from inpatient (acute,
extended, observation, and non-VA care) and outpatient
files from January 1, 2004 through October 1, 2007. This
period spans the EHR/QI data collection from the earliest
diagnosis of CRC in EHR/QI to one year after the latest
diagnosis of CRC when EHR/QI surveillance data collec-
tion ended. For the inpatient file, the main, procedure,
and surgery datasets were included. CRC-related care
events were identified using relevant Current Procedure
Terminology (CPT-4) procedure codes and Inter-
national Classification of Diseases, 9th revision, Clinical
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Modification (ICD-9-CM) diagnosis codes (Table 1).
The ICD-9 codes are used in both inpatient and out-
patient administrative files and CPT-4 codes are used
in the outpatient administrative data files so both types
of codes are required to identify all diagnoses and pro-
cedures. VA administrative data are based on informa-
tion entered into CPRS and coded (e.g., ICD-9 and
CPT-4 codes) at the time of the patient encounter. VA
administrative data are then stored in a centralized loca-
tion from across the VA healthcare system. We obtained
the VA administrative data for this study by querying the
VA national data system (NDS) for records containing any
of the codes listed in Table 1 during the study period for
the study patients. Demographic variables were identified
from the visit dataset in the outpatient file. In addition,
demographic characteristics were also drawn from the VA
Central Cancer Registry (VACCR) for a separate compari-
son with the EHR/QI data.
Variables collected
CRC-related care included both curative intent treat-
ments and surveillance tests done after CRC diagnosis
to detect CRC recurrence. Receipt of the following
curative intent treatments were drawn from the EHR/
QI and VA administrative data: surgical resection, neo-
adjuvant chemotherapy, and adjuvant chemotherapy,
and neoadjuvant radiation, and adjuvant radiation therap-
ies. In VA administrative data, chemotherapy or radiation
prior to the date of surgical resection in EHR/QI data were
considered neoadjuvant treatment and chemotherapy or
radiation after this date was considered adjuvant treatment;
the completion of treatment courses was not evaluated.
Receipt of the following surveillance tests [20] were
compared between the EHR/QI and VA administrative
data: colonoscopy [21], CEA test [5], and physician
visits. Two administrative records were considered to be
the same event if both events 1) were of the same type
and 2) occurred within a specified time window of each
other. Colonoscopies and surgeries that occurred within
30 days of each other were considered the same event
and CEA tests and physician visits that occurred within
7 days of each other were considered the same event
[22]. In these cases, the event that occurred first was
considered the “true” event because, for a short time
window, the repeat test is likely a completion or follow-
up to the first test and not an independent event. These
time windows were applied to every instance of every
test.
The demographic variables of date of birth, date of
death, gender, race, and marital status were collected
from EHR/QI and VA administrative data as well as the
VACCR.
Analysis
Patients in the VA administrative data were matched
with patients in the EHR/QI by their social security
number. For demographic variables, values from VA ad-
ministrative data were compared to EHR/QI data for ac-
curacy and completeness (see Table 2). The accuracy of
a variable was assessed using the percent agreement be-
tween the values in EHR/QI and VA administrative data
for patients who have non-missing observations in both
sources. The completeness of a variable was the percent-
age of patients with an observation in the EHR/QI data
who also had the observation in VA administrative data.
While this metric misses EHR/QI false negative tests, it
does demonstrate the ability of the VA administrative
data to identify outcomes that would also be identified
by manual abstraction.
To evaluate the receipt of individual surveillance test
events, the accuracy of VA administrative data relative
to the EHR/QI data for events of each type of post-
diagnosis test was assessed using the positive predictive
value relative to the EHR/QI data. The advantage of the
positive predictive value is that it assesses the overall
Table 1 ICD-9 diagnostic, CPT-4 procedure, and laboratory
codes used to identify CRC-related treatments and test events
Test or Treatment ICD-9 diagnostic code CPT-4 procedure code
Colonoscopy 45.22, 45.23, 45.25, 45.41,
45.42, 45.43, 48.36
44,388, 44,389, 44,392,
44,393, 44,394,45,378,
45,380, 45,382, 45,383,
45,384, 45,385, 45,391,
G0105
Carcinoembryonic
antigen (CEA)
795.81 82,378
Physician visit 99201-99205, 99211-
99215, 99241-99245,
99381-99387, 99391-97
Surgical resectiona 45.7, 45.71-45.79, 45.8,
45.81- 45.89, 48.4, 48.41-
48.49, 48.5, 48.51-48.59,
48.6 48.61-48.69
44140, 44141, 44143-
44160, 44024-44213
Chemotherapy 99.25, V58.1, V66.2, V67.2,
E930.7, E933.1
36260, 36640, 96400-
96425
Radiation 92.2, 92.21-92.26,92.29;
92.3-92.39, V58.0, V66.1,
V67.1
77260-77525
aCooper et al., 2000 [33] identified the ICD-9 and CPT-4 codes associated with
the 4 levels of surgery documented in SEER: biopsy, local excision, bypass surgery,
and resection. Only the codes associated with “resection” were used
Table 2 Metrics used to evaluate the accuracy of the VA
administrative data relative to EHR/QI manual abstraction data
Variable Accuracy
Demographics Percent agreement
Post-diagnosis treatment events Positive predictive
value
Receipt of type of care at any time while
eligible
Kappa statistic
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receipt of a test and not individual test events; this is im-
portant because it was unclear whether the EHR/QI
continued to collect surveillance events once the recom-
mended surveillance was achieved. The completeness of
VA administrative data for events of each type of post-
diagnosis test was the fraction of test events in the EHR/
QI also present in VA administrative data.
To evaluate whether a type of care (curative treatment
or surveillance test) was received at any time during the
eligible time period, the accuracy of VA administrative
data were determined using kappa statistics for agree-
ment versus the EHR/QI data. The kappa statistics for
agreement for each type of care was based on comparing
the EHR/QI and VA administrative data predicted re-
ceipt of care for individual patients over the eligible time
interval. In general, kappa values <0 indicate less than
chance agreement, 0.01–0.20 indicate slight agreement,
0.21–0.40 indicate fair agreement, 0.41–0.60 indicate
moderate agreement, 0.61–0.80 indicate substantial
agreement, and 0.81–1.00 indicate almost perfect agree-
ment [23]. The sensitivity for identifying whether a type
of CRC-related care was received at any time during the
eligible time period was the fraction of patients docu-
mented by the EHR/QI data as receiving a type of care
who also had documentation of that care in VA adminis-
trative data.
All analyses were performed using R 2.15.2.
Results
The EHR/QI project completed chart abstraction for 624
patients with AJCC collaborative stage I, II, or III CRC; as
shown in Table 3, the demographic characteristics of the
EHR/QI cohort are similar to those of all patients diag-
nosed with AJCC collaborative stage I-III CRC in the
VACCR during the study period. A total of 618 patients
(99.0 %) identified in the EHR/QI process were also identi-
fied in VA administrative data. A total of 413 of these
patients were also present in the VACCR with AJCC col-
laborative stage I, II, or III cancer.
According to the EHR/QI data abstraction, the average
age at the diagnosis date was 69.0 years and the popula-
tion was predominantly male (98.1 %) and white
(80.6 %) as shown in Table 3. Roughly half (50.8 %) of
the patients were married. CRC cases were fairly evenly
distributed between stage I (30.0 %), II (37.1 %), and III
(33.0 %) and the majority of patients had colon cancer
(69.7 %). Most patients had a surgical procedure (95.8 %;
598/624) and some received neoadjuvant chemotherapy
(13.0 %; 81/624), adjuvant chemotherapy (27.1 %; 169/
624), neoadjuvant radiation (13.6 %; 85/624), or adjuvant
radiation (5.6 %; 35/624). Post-diagnosis care was moni-
tored for an average of 10.4 months (7.9 month standard
deviation).
Percent agreement and completeness of demographic
characteristics
For the 618 of 624 patients in EHR/QI data also in the
VA administrative data, the agreement between the
EHR/QI and VA administrative data for demographic
and CRC variables was 98.7 % (610/618) for date of
birth, 98.1 % (606/618) for date of death, 100.0 % (618/
618) for gender, 93.0 % (213/229) for race, and 91.4 %
(512/560) for marital status (Table 3). VA administrative
data contained complete data for all patients (100 %, 618/
618) for date of birth, gender, and marital status. However,
the VA administrative data contained patient data for race
for only 37.9 % (234/618) of patients.
Percent agreement and completeness of cancer and
clinical characteristics
For the 413 EHR/QI patients also present in the
VACCR with stage I, II, or III cancer, the CRC stage in
the VACCR agreed with the EHR/QI data for 95.2 %
(393/413) of patients and the agreement for CRC loca-
tion was 97.0 % (392/407 with missing data for 6 EHR/
QI patients). The agreement for number of lymph
nodes examined and number of lymph nodes positive
for cancer were 94.3 % (367/389 with missing data in
EHR/QI for 19 patients and VACCR for 5 patients) and
98.2 % (385/392 with missing data in EHR/QI for 19
patients and VACCR for 8 patients), respectively. The
agreement between the C4 and the VACCR for demo-
graphic and CRC variables was 98.3 % (406/413) for age
at diagnosis, 100.0 % (413/413) for gender, 98.5 % (392/
398) for race, and 95.2 % (357/375) for marital status.
The VACCR contained complete patient data (100 %,
413/413) for age at diagnosis, gender, and marital status
and race data for 96.3 % (398/413) of patients.
Completeness and positive predictive value of VA
administrative data for post-diagnosis test events
VA administrative data identified 174 of 229 (76.0 %;
95 % CI, 70.1–81.1 %) post-diagnosis colonoscopies,
294 of 1,117 (26.3 %; 95 % CI, 23.8–29.0 %) CEA
tests, and 2,027 of 2,396 (84.6 %; 95 % CI, 83.1–
86.0 %) physician visit events in the EHR/QI data
(Table 4).
The positive predictive value of VA administrative data
for post-diagnosis test events identified in the EHR/QI
data was 61.1 % (95 % CI, 55.1–66.7 %) for colonoscopy,
54.1 % (95 % CI, 49.8–58.4 %) for CEA tests, and 31.9 %
(95 % CI, 30.7–33.0 %) for physician visits (Table 4). A
lower positive predictive value indicated that more
events were identified in the administrative data that
were not also identified by C4.
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Table 3 Patient characteristics and agreement between VA administrative data and EHR/QI chart abstraction
Characteristic EHR/QI (N = 624) All stage I-III VACCR (N = 4,870) p-value VA administrative data
(N = 618)
EHR/QI vs. VA
administrative data
VA Central Cancer Registry
(N = 413)
EHR/QI vs. VA Central
Cancer Registry
Demographic
Age at diagnosis –
median (q1, q3)
69.0 years (60.3, 78.1) 69 years (60,77) 0.64 N/A N/A 69 years (60, 78) 98.3 % (406 / 413)
Date of birth - % (n / N) 98.7 % (610 / 618) N/A
Date of death - % (n / N) 98.1 % (606 / 618) N/A
Gender - % (n / N) 0.84 100 % (618 / 618) 100 % (413 / 413)
Male 98.1 % (612 / 624) 97.9 % (4,768 / 4,870) 98.2 % (607 / 618) 99.0 % (409 / 413)
Female 1.9 % (12 / 624) 2.1 % (102 / 4,870) 1.8 % (11 / 618) 1.0 % (4 / 413)
Unknown 0.0 % (0 / 624) 0.0 % (0 / 4,870) 0.0 % (0 / 618) 0.0 % (0 / 413)
Race - % (n / N) 0.27 93.0 % (213 / 229) 98.5 % (392 / 398)
White 80.6 % (503 / 624) 81.8 % (3,986 / 4,870) 30.6 % (189 / 618) 80.1 % (331 / 413)
Black 12.8 % (80 / 624) 15.2 % (739 / 4,870) 7.0 % (43 / 618) 14.8 % (61 / 413)
Other 4.2 % (26 / 624) 1.0 % (24 / 4,870) 0.3 % (2 / 618) 2.9 % (12 / 413)
Unknown 2.4 % (15 / 624) 2.1 % (100 / 4,870) 62.1 % (384 / 618) 2.2 % (9 / 413)
Marital status - % (n / N) 0.73 91.4 % (512 / 560) 95.2 % (357 / 375)
Single 39.9 % (249 / 624) 39.1 % (1,905 / 4,870) 51.6 % (319 / 618) 48.9 % (202 / 413)
Married 50.8 % (317 / 624) 51.7 % (2,517 / 4,870) 48.4 % (299 / 618) 51.1 % (211 / 413)
Unknown 9.3 % (58 / 624) 9.2 % (448 / 4,870) 0.0 % (0 / 618) 0.0 % (0 / 413)
Cancer
Location 0.45 N/A 97.0 % (392 / 404)
Colon 69.7 % (435 / 624) 71.1 % (3,465 / 4,870) N/A 74.6 % (308 / 413)
Rectum 28.2 % (176 / 624) 26.7 % (1,298 / 4,870) N/A 25.4 % (105 / 413)
Unknown 2.1 % (13 / 624) 2.2 % (107 / 4,870) N/A 0 % (0 / 413)
AJCC collaborative stage 0.70 N/A 95.2 % (393 / 413)
I 30.0 % (187 / 624) 31.0 % (1,511 / 4,870) N/A 30.5 % (126 / 413)
II 37.0 % (231/624) 36.2 % (1,763 / 4,870) N/A 36.8 % (152 / 413)
III 33.0 % (206 / 624) 32.7 % (1,596 / 4,870) N/A 32.7 % (135 / 413)
Curative treatment - %
(n / N)
Surgical resection 95.8 % (598 / 624) N/A 91.7 % (567 / 618) 92.7 % (573 / 618) N/A N/A
Date of Surgery N/A 96.9 % (540 / 557) N/A N/A
Neoadjuvant
chemotherapy
13.0 % (81 / 624) N/A 5.8 % (36 / 618) 91.7 % (567 / 618) N/A N/A
Sherer
et
al.BM
C
H
ealth
Services
Research
 (2016) 16:50 
Page
5
of
10
Table 3 Patient characteristics and agreement between VA administrative data and EHR/QI chart abstraction (Continued)
Neoadjuvant radiation 13.6 % (85 / 624) N/A 7.6 % (47 / 618) 92.9 % (574 / 618) N/A N/A
Adjuvant chemotherapy 27.1 % (169 / 624) N/A 30.1 % (186 / 618) 81.6 % (504 / 618) N/A N/A
Adjuvant radiation 5.6 % (35 / 624) N/A 21.8 % (135 / 618) 80.3 % (496 / 618) N/A N/A
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Sensitivity and agreement for receipt of CRC-related care
(treatments and tests) at any time during eligible period
For treatments, VA administrative data identified 557 of
592 (94.1 %; 95 % CI, 91.8–95.6 %) patients who received
surgical resection in the EHR/QI data; and the date of
surgical resection agreed between the two data sources
for 540 of these 557 (96.9 %; 95 % CI, 95.2–98.1 %) pa-
tients. VA administrative data identified 33 of 36
(91.7 %; 95 % CI, 76.4–97.8 %) patients who received
neoadjuvant chemotherapy, 121 of 187 (65.1 %; 95 %
CI, 57.7–71.8 %) who received adjuvant chemotherapy,
44 of 85 (51.8 %; 95 % CI, 40.7–62.6 %) who received
neoadjuvant radiation, and 24 of 35 (68.6 %; 95 % CI,
50.6–82.6 %) who received adjuvant radiation (Table 5).
VA administrative data and the EHR/QI data showed
moderate agreement for receipt of neoadjuvant radi-
ation (κ = 0.60; 95 % CI, 0.49–0.71), adjuvant chemo-
therapy (κ = 0.55; 95 % CI, 0.48–0.63), and neoadjuvant
chemotherapy (κ = 0.53; 95 % CI, 0.40–0.65). The agree-
ment was fair for the receipt of surgical resection (κ = 0.38;
95 % CI, 0.21–0.56) and adjuvant radiation (κ = 0.21; 95 %
CI, 0.09–0.34).
For post-diagnosis tests, VA administrative data identi-
fied 171 of 200 (85.5 %; 95 % CI, 79.7–89.9 %) patients
who received a colonoscopy in the EHR/QI data, 190 of
382 (49.7 %; 95 % CI, 44.6–54.9 %) who received a CEA,
and 498 of 500 (99.6 %; 95 % CI, 98.4–99.9 %) who re-
ceived a physician visit. VA administrative data and the
EHR/QI showed almost perfect agreement for whether
there was a primary care visit (κ = 0.83; 95 % CI, 0.78–
0.89) at any time during the eligible period. The agree-
ment for colonoscopy was moderate (κ = 0.66; 95 % CI,
0.59–0.72) and the agreement for CEA tests was fair (κ
= 0.35; 95 % CI, 0.28–0.42).
The supplemental accuracy measures of the specificity,
positive predictive value, and negative predictive value of
receipt of a type of care during the eligible period for
VA administrative data versus the EHR/QI data are pro-
vided in Table 6.
Discussion
The use of cancer registries linked with administrative
data represents a widely accepted methodologic approach
in cancer health services research to identify cancer treat-
ment and surveillance care that may not be captured by
tumor registries alone. Linked SEER-Medicare databases
have been used to develop relapse algorithms [24]; evalu-
ate receipt of CRC surgical resection [25], chemotherapy
[26], and radiation [27]; and study cancer screening rates
[28]. Similarly, linkages between VA cancer registries and
VA administrative data could be used to evaluate care
received within the VA system if this care is adequately
captured in administrative data. The methodologic study
presented here evaluated the completeness and accuracy
of VA administrative data for CRC-related care by com-
paring procedures identified in the administrative data
Table 5 Sensitivity and kappa static for receipt of any CRC-related care in VA administrative data versus EHR/QI manual data abstraction
Test or Treatment Sensitivity (95 % CI) Kappa statistic
(95 % CI)
EHR/QI and VA
administrative data
Only EHR/QI
data
Only VA
administrative data
Neither data
source
Colonoscopy 0.855 (0.797, 0.899) 0.66 (0.59, 0.72) 171 29 69 349
Carcinoembryonic
antigen
0.497 (0.446, 0.549) 0.35 (0.28, 0.42) 190 192 24 212
Physician visit 0.996 (0.984, 0.999) 0.83 (0.78, 0.89) 498 2 27 91
Surgical resection 0.941 (0.918, 0.956) 0.38 (0.21, 0.56) 557 35 10 16
Neo-adjuvant
chemotherapy
0.917 (0.764, 0.978) 0.53 (0.40, 0.65) 33 3 48 534
Adjuvant
chemotherapy
0.651 (0.577, 0.718) 0.55 (0.48, 0.63) 121 65 48 383
Neo-adjuvant
radiation
0.518 (0.407, 0.626) 0.60 (0.49, 0.71) 44 41 3 530
Adjuvant radiation 0.686 (0.506, 0.826) 0.21 (0.09, 0.34) 24 11 111 472
Table 4 Completeness and PPV for post-diagnosis test events in VA administrative data versus EHR/QI manual data abstraction
Test Completeness (95 % CI) Positive predictive valuea
(95 % CI)
EHR/QI and VA
administrative data
Only EHR/QI data Only VA
administrative data
Colonoscopy 0.760 (0.701, 0.811) 0.611 (0.551, 0.667) 174 55 111
Carcinoembryonic
antigen
0.263 (0.238, 0.290) 0.541 (0.498, 0.584) 294 823 249
Physician visit 0.846 (0.831, 0.860) 0.319 (0.307, 0.330) 2,027 369 4,334
aA lower positive predictive value indicated that more events were identified in the administrative data that were not also identified by C4
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with those from a manual abstraction of electronic health
records performed during the course of a quality improve-
ment collaborative.
There was good agreement between VA administrative
and EHR/QI data for demographic variables (91.4 % to
100 % agreement) and CRC treatments received (80.3 %
to 92.9 % agreement). The agreements for treatment are
similar to what has been observed in Medicare vs. rec-
ord review for receipt of chemotherapy (88 % colon and
91 % rectal) [26] and radiation (93.5 %) [27]. As previ-
ously noted by others [29, 30], there is considerable
missingness in VA administrative data for race (62.1 %
missing). Our result is consistent with what is known
about race in VA administrative data; according to the
VIReC Technical Report: VA Race Data Quality, race is
missing from 33–37 % of VA administrative data records
for 2004–2005, although the quality of the data has been
improving with time [31]. The missingness of race in the
VA cancer registry was considerably lower (2.2 %) and
may be considered as the primary source of race for
studies involving VA patients with cancer.
VA administrative data were reasonably complete for
post-diagnosis colonoscopy (76 %) and physician visit
(84.6 %) events but the completeness for the CEA
(26.3 %) events was considerable lower. This lower com-
pleteness for the CEA tests may be due to the coding of
many of these procedures in laboratory data, which was
not considered here, or a lower rate of coding laboratory
tests in the administrative data. The agreement for re-
ceipt of colonoscopy (κ = 0.66) was moderate but lower
than the almost perfect agreement that has been ob-
served between Medicare data and health record review
(κ = 0.89) [10]. But, as discussed below, the majority of
the disagreements in VA data were due to colonoscopies
in the VA administrative data that were not documented
by the EHR/QI.
There were a significant number of procedures of all
types identified in VA administrative data but not by the
EHR/QI data manual abstraction process. For example,
the positive predictive value for colonoscopy after
diagnosis was 61.1 %, or 111 of the 285 colonoscopy
events in VA administrative data were not in the EHR/
QI data. This difference between administrative claims
data and chart abstraction can be explained by either
“false-positive” claims or incomplete/inaccurate abstrac-
tion. The latter explanation is the more compelling. Spe-
cifically, it was unclear whether the EHR/QI data
continued to collect surveillance events once the recom-
mended surveillance was achieved; this would lead to
apparent false positives in the VA administrative data
which would lower the positive predictive value. Also,
differences between administrative data and manual ab-
straction may occur if abstractors misinterpreted coding
directions (e.g., difficulty in defining a physician visit was
noted as a limitation of the EHR/QI [9]), did not collect
all procedures (e.g., local site variations [32] or patient
met the indicator criteria so no additional procedures
were collected), or simply missed procedures. Because
the C4 was undertaken as part of a quality improvement
effort rather than a systematic CRC surveillance study,
these abstraction errors are likely to be more prevalent
in the C4 data than traditional research studies. Previous
studies stemming from the C4 have identified the great-
est opportunity for improvement as timely surveillance
of cancer survivors, however due to missing data, previ-
ous studies may have overestimated the size of the qual-
ity gap [7, 9]. Also of note is that colon and rectal
cancer were not differentiated using VA administrative
data which – because, in the EHR/QI, there are indica-
tor variables for neoadjuvant chemotherapy and neoad-
juvant radiation of rectal but not colon cancer as well
as no indicator variable for adjuvant radiation [9] –
likely led to many of the “false-positives” for these vari-
ables in VA administrative data.
There are several potential limitations to this study.
While the receipt of CRC surveillance procedures was
compared, the indication for the procedure (i.e. whether
the procedure was for surveillance or diagnostic) was
unknown. Without the indication to identify whether
procedures were related, time windows were used to
Table 6 Specificity, PPV, and NPV for receipt of any CRC-related care in VA administrative data versus EMR/QI manual data
abstraction
Test or Treatment Specificity (95 % CI) Positive Predictive Value (95 % CI) Negative Predictive Value (95 % CI)
Colonoscopy 0.834 (0.795, 0.869) 0.713 (0.650, 0.768) 0.923 (0.890, 0.947)
Carcinoembryonic antigen 0.898 (0.851, 0.932) 0.888 (0.836, 0.925) 0.524 (0.475, 0.574)
History and physical 0.771 (0.682, 0.841) 0.949 (0.925, 0.965) 0.978 (0.917, 0.996)
Surgery 0.615 (0.407, 0.791) 0.982 (0.967, 0.991) 0.314 (0.195, 0.460)
Neo-adjuvant chemotherapy 0.918 (0.891, 0.938) 0.407 (0.301, 0.522) 0.994 (0.982, 0.999)
Adjuvant chemotherapy 0.889 (0.854, 0.916) 0.716 (0.641, 0.781) 0.855 (0.818, 0.886)
Neo-adjuvant radiation 0.994 (0.982, 0.999) 0.936 (0.814, 0.983) 0.928 (0.903, 0.947)
Adjuvant radiation 0.810 (0.775, 0.840) 0.178 (0.119, 0.255) 0.977 (0.958, 0.988)
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identify related procedures but this may combine two
unrelated procedures together. There was also no docu-
mentation of when each manual search of the EHR/QI
was conducted. We assumed that the final search for a
patient was conducted on the last documented date in
the EHR/QI data for that patient, but it is possible that
subsequent searches were conducted that found no new
information. We also assumed that all EHR/QI variables
were searched for during each manual abstraction, but it
is possible that not all variables were searched for dur-
ing each examination of the health record. Of note, our
study represents a comparison of administrative data
and electronic health records in the VA system. While
these methods may serve as a guide, they should be val-
idated in other healthcare systems. In addition, the VA
CRC patient population is predominantly male and di-
agnosed at an earlier stage than the general population
[1] so the study cohort may not be generalizable.
Finally, the comparison on patient characteristics in
Table 3 was based patients whose data was not missing
so there is the potential for selection bias.
Conclusions
In summary, national Veterans Affairs administrative
data can be a powerful tool to assess the quality of
CRC surveillance care. However, before measures of
care quality can be instituted, the accuracy of these
data should be examined. Results from this study sug-
gest that VA administrative data are accurate and
complete for non-race demographic variables, receipt
of CRC treatment, colonoscopy, and physician visits
and may be a potential alternative to manual abstrac-
tion for the measurement of CRC care. However alter-
native data sources will be necessary to capture patient
race and receipt of CEA tests.
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